EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06249945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06249945
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06249945. Randomized; single masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Acronym
EMPA-PRED
Condition
End Stage Renal Disease on Dialysis
Intervention (Drug)
Empagliflozin 25 MG
Intervention (Drug)
Placebo
Lead sponsor
National Taiwan University Hospital (class: other)
Collaborator
Shin Kong Wu Ho-Su Memorial Hospital (class: other)

Record details

Record id
cardio:ct-nct06249945
Content hash
43251a6a06a54e99e336fc528fe6fea7be0087ee2210df468c654b53e83d551f